What is the price-to-earnings ratio of Neovacs?
The price-earnings ratio of Neovacs is currently 52.74.
Neovacs P/S 2024
Neovacs P/S
52.74
Ticker
ALNEV.PA
ISIN
FR0004032746
WKN
A1CVKR
As of Dec 18, 2024, Neovacs's P/S ratio stood at 52.74, a 3,694.24% change from the 1.39 P/S ratio recorded in the previous year.
The Neovacs P/S history
Neovacs Aktienanalyse
What does Neovacs do?
Neovacs SA is a French biotechnology company specializing in the development of immunotherapies for the treatment of autoimmune diseases and cancer. It was founded in 1993 by Pierre Vandepapeliere and is headquartered in Paris. The company has a history of groundbreaking discoveries and continuous innovation. Its business model is based on the combination of cutting-edge research and the development of customized therapies for the treatment of autoimmune diseases and cancer. Neovacs SA identifies specific proteins that trigger an immune response against the body's own cells and tissues, and develops Kinoid vaccines to neutralize these proteins and stop the autoimmune reaction. It is also specialized in the development of immunotherapies for the treatment of cancer. The main divisions of Neovacs SA are clinical development, regulatory affairs, and the manufacturing of Kinoid vaccines. It has achieved an impressive track record in the clinical development of Kinoid vaccines and collaborates with leading universities, hospitals, and research institutions to support its research and development activities. The company currently offers a range of different Kinoid vaccines for the treatment of autoimmune diseases, including a product for the treatment of lupus, a product for the treatment of rheumatoid arthritis, and a product for the treatment of chronic hepatitis B. All of these products are currently in Phase 2 development. Another important product being developed by Neovacs SA is an immunotherapeutic for the treatment of cancer. Known as TNF-Kinoid, the product aims to enhance the body's immune defense against cancer cells and inhibit tumor growth. It has shown promising results in Phase 1 clinical development and is currently in Phase 2 development. Neovacs SA is a strong and growing company in a rapidly evolving sector of biotechnology. It has an impressive track record in the clinical development of immunotherapies for the treatment of autoimmune diseases and cancer, and is well-positioned to continue making significant contributions to healthcare. Neovacs ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Neovacs's P/S Ratio
Neovacs's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Neovacs's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Neovacs's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Neovacs’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Neovacs stock
How has the price-earnings ratio of Neovacs changed compared to last year?
The price-to-earnings ratio of Neovacs has increased by 3,694.24% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Neovacs high compared to other companies?
Yes, the price-to-earnings ratio of Neovacs is high compared to other companies.
How does an increase in the price-earnings ratio of Neovacs affect the company?
An increase in the price-earnings ratio of Neovacs would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Neovacs affect the company?
A decrease in the price-earnings ratio of Neovacs would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Neovacs?
Some factors that influence the price-earnings ratio of Neovacs are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Neovacs pay?
Over the past 12 months, Neovacs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neovacs is expected to pay a dividend of 0 EUR.
What is the dividend yield of Neovacs?
The current dividend yield of Neovacs is .
When does Neovacs pay dividends?
Neovacs pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Neovacs?
Neovacs paid dividends every year for the past 0 years.
What is the dividend of Neovacs?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Neovacs located?
Neovacs is assigned to the 'Health' sector.
Wann musste ich die Aktien von Neovacs kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Neovacs from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Neovacs pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Neovacs in the year 2023?
In the year 2023, Neovacs distributed 0 EUR as dividends.
In which currency does Neovacs pay out the dividend?
The dividends of Neovacs are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Neovacs
Our stock analysis for Neovacs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neovacs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
